San Diego-primarily based Viking Therapeutics marked alone as a significant competitor during the weight loss drug market place in February after revealing promising facts from a mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when provided to be a weekly injection As well as in March